

Supplemental Table 5. Univariate analysis for patients exceeding the Milan criteria (N=3386)

		N	Tumor-free survival rate (%)				<i>P</i> *
			1-yr	3-yr	5-yr	10-yr	
Age (yrs)	≤40	572	60.4	40.6	36.4	20.4	<0.001
	40-50	1132	64.7	38.3	31.7	20.7	
	>50	1682	71.9	54.3	45.2	26.6	
Sex	Male	3101	67.4	46.3	39.1	25.9	0.54
	Female	285	69.8	51.0	41.5	0	
HBsAg	Positive	3066	67.4	46.4	39.1	22.9	0.55
	Negative	320	70.0	51.1	41.7	38.2	
Cirrhosis	Positive	2877	68.5	47.1	40.5	24.5	0.03
	Negative	509	62.7	44.7	33.0	25.8	
Hepatectomy	Yes	497	69.0	40.7	33.6	—	0.30
	No	2889	67.4	47.9	40.4	25.1	
Adjuvant therapy	Yes	1290	67.9	49.0	41.4	25.0	0.37
	No	2096	67.5	45.0	37.5	24.1	
Differentiation (Edmondson)	High	1035	72.9	53.4	44.4	24.4	<0.001
	Moderate	1895	66.4	44.6	38.0	31.2	

	Low or none	456	60.3	38.7	31.7	10.9	
Tumor staging	I-II	1471	77.1	59.0	51.8	30.7	<0.001
(TNM)	III	1540	60.8	38.8	31.1	23.1	
	IV	375	57.9	30.2	18.7	—	
Vascular invasion	Positive	1138	5	34.8	27.8	17.2	<0.001
(Pathology)	Negative	2248	71.2	53.8	46.1	29.5	
Tumor burden	≤8	2029	73.8	52.5	45.4	28.1	<0.001
(cm)	>8	1357	56.6	34.9	29.9	—	
Number	≤3	2504	67.4	46.8	38.9	23.0	0.70
	>3	882	68.3	46.8	40.1	28.2	
AFP (ng/mL)	≤100	1503	75.2	58.4	50.5	31.7	<0.001
	100-400	571	70.9	46.2	40.1	34.2	
	>400	1312	57.6	33.9	26.4	11.3	
MELD	≤10	1685	68.1	47.5	39.1	28.2	0.66
	>10	1701	67.2	46.0	39.6	18.0	
Donor origin	Living donor	108	76.2	53.9	45.5	—	0.21
	Cadaveric	3278	67.4	46.5	39.0	23.8	

Year of transplant	<2005	447	56.8	36.3	32.9	20.4	<0.001
	2005-2010	2214	67.4	49.7	41.0	—	
	>2010	725	71.5	—	—	—	

Note. * Log-rank test; HBsAg, hepatitis B surface antigen; AFP, α -fetoprotein; MELD, model for end-stage liver diseases.